克里索提尼布通过阻断膜上皮细胞中的自流来诱导肺毒性
Yuanteng Zhang1, Zizheng Gao2, Zezheng Pan2
1Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China; Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
克里佐替尼 (crizotinib) 通过阻断膜细胞的自,导致炎症而导致肺损伤. 甲福明可以通过恢复自和减少纤维化来保护肺功能.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 毒理学 毒理学 毒理学
背景情况:
- 克里佐替尼 (crizotinib) 是一种先进的非小细胞肺癌 (NSCLC) 的第一线治疗方法,该癌症具有形淋巴瘤激酶 (ALK) 基因变异.
- 肺毒性,包括严重的间歇性肺病,是克里佐替尼治疗的显著限制.
- 由于crizotinib引起的肺损伤以及有效的对策的确切机制在很大程度上仍未被阐明.
研究的目的:
- 为了研究crizotinib诱导的肺毒性机制.
- 建立一个可靠的体内模型来研究这种毒性.
- 为了确定潜在的治疗策略,以减轻crizotinib诱导的肺损伤.
主要方法:
- 一个体内小鼠模型使用C57BL/6小鼠连续给药crizotinib (100 mg/kg/天6周) 开发.
- 膜上皮细胞系 (BEAS-2B和TC-1) 在体外用crizotinib进行治疗.
- 评估了自流,亡率,免疫细胞招募和肺纤维化.
- 评估了甲胺对克里佐替尼布诱导的肺损伤的影响.
主要成果:
- 在小鼠中,克里佐替尼布的使用诱导了间歇性肺病,反映了临床观察.
- 克里佐替尼治疗增加了膜上皮细胞的亡.
- 克里佐替尼抑制了自流,导致了亡和随后的免疫细胞招募,表明自功能受损是肺损伤的关键因素.
- 甲胺治疗恢复了自流量,减少了巨细胞招募和肺纤维化,改善了肺功能障碍.
结论:
- 克里索提尼布诱导的肺毒性源于膜上皮细胞的亡和随后的炎症,由阻塞的自流驱动.
- 梅特福明通过恢复自和减少炎症反应,显示出作为克里佐替尼诱导肺毒性的治疗剂的前景.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
